Alzheimer’s Research UK has responded to an announcement that could see new legislation aimed at providing faster access to medicines. The Medicines and Medical Devices Bill, announced in this week’s Queen’s Speech, would see measures designed to improve treatments and give patients access to innovative new medicines.
Hilary Evans, Chief Executive of Alzheimer’s Research UK, said:
“We would welcome legislation that could ensure future treatments for dementia could be made available to people without delay. The sheer number of people with dementia means that new treatments could pose significant practical and financial challenges to the health system, and it will be important for any new Bill to address these. Through the Dementia Access Taskforce, Alzheimer’s Research UK is working with government, health bodies and the pharmaceutical industry to find solutions to these challenges, and it will be vital for this work to inform future policy to improve how new medicines reach the people who need them.
“We must also increase investment in dementia research if we are to expand the number of treatments being tested and give them the best chance of success. In just two years, one million people will be living with dementia in the UK, and the cost of dementia care will continue rising unless we find new ways to treat and prevent the condition. Investing just 1% of the annual cost of dementia into research could make the difference and help bring about treatments that could change lives.”
Learn more about the Dementia Access Taskforce at https://www.alzheimersresearchuk.org/taskforce